Full-Time

Director – Biostatistics

Posted on 8/5/2024

Revolution Medicines

Revolution Medicines

501-1,000 employees

Develops targeted therapies for RAS-driven cancers

Biotechnology
Healthcare

Compensation Overview

$231k - $265kAnnually

+ Equity Awards + Benefits + Learning and Development Opportunities

Senior, Expert

San Carlos, CA, USA

Hybrid position requiring in-office presence.

Category
Public Health
Biology Lab & Research
Biology & Biotech
Required Skills
R
Data Analysis
Requirements
  • Ph.D. or M.S. in Statistics/Biostatistics, minimum 6 years (for Ph.D.) and 10 years (for M.S.) of experience in biotech/pharma industry as a statistician. Level will be determined based on the relevance of experience.
  • Hands-on experience in design and analysis of phase 3 oncology trials is a must.
  • Solid knowledge in ICH and other regulatory requirements related to biostatistical activities and clinical trials.
  • Excellent verbal and written communication skills are required.
  • Good interpersonal and project management skills are essential.
  • Proficiency in SAS and/or R.
Responsibilities
  • Lead strategic, statistical thinking and contributions to clinical development plans.
  • Represent Biostatistics function on cross-function teams at program/indication level and serve as a lead statistician for oncology studies.
  • Collaborate with various functions on study design and planning, protocol development, statistical analysis plan and analysis specifications.
  • Provide statistical support for study protocol development, analysis plan and specification through direct involvement and/or providing guidance to junior staff.
  • Plan and prepare independent data monitoring committee (DMC), coordinate with independent statistical data analysis center for DMC and study team for periodic DMC reviews.
  • Collaborate with data management and clinical operations over the course of clinical studies to provide statistical input to study conducts and database development as well as data collection and cleaning activities.
  • Collaborate with statistical programming to ensure that appropriate programs and documentations are being developed for datasets development and outputs generation, and ensure the statistical analyses specified in scientific protocols and/or analysis plans are conducted appropriately.
  • Provide statistical input and leadership to the development of global health authority documents, regulatory interaction and response to health authority submissions.
  • Provide statistical support for clinical publications, assist in data interpretation to ensure consistency and accuracy in data presentation.
  • Drive and lead department initiatives, best practices, and guidelines.
  • Keep abreast in new developments in statistics, drug development, and regulatory guidance and share knowledge with functional and cross-functional team members.

Revolution Medicines develops treatments specifically for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main products are RASON Inhibitors, designed to target and inhibit RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses solely on RAS-driven cancers, allowing them to carve out a niche in the oncology market. Their goal is to transform cancer treatment by providing effective targeted therapies for patients suffering from these challenging conditions.

Company Stage

IPO

Total Funding

$219.8M

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

-2%

1 year growth

-3%

2 year growth

7%
Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of EQRx adds over $1 billion in capital for R&D.
  • FDA fast-tracking supports their RAS-targeted therapy pipeline.
  • Growing interest in targeted cancer therapies boosts investment opportunities.

What critics are saying

  • EQRx acquisition may pose integration challenges and cultural clashes.
  • $600M public stock offering could lead to shareholder dilution.
  • Focus on RAS-addicted cancers limits market scope and increases competition risk.

What makes Revolution Medicines unique

  • Revolution Medicines reconfigures natural substances into best-in-class cancer therapies.
  • Their Tri Complex Inhibitor platform targets RAS proteins driving cancer growth.
  • Exclusive license with University of Illinois enhances their unique synthesis technology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

INACTIVE